about
sameAs
Imatinib mesylate in chordomaSoft tissue sarcoma nomograms and their incorporation into practice.Treatment of soft tissue sarcoma: a focus on earlier stages.Outcome prediction in primary resected retroperitoneal soft tissue sarcoma: histology-specific overall survival and disease-free survival nomograms built on major sarcoma center data sets.Chordoma: natural history and results in 28 patients treated at a single institution.Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas.Response to imatinib plus sirolimus in advanced chordoma.Chordoma of the mobile spine and sacrum: a retrospective analysis of a series of patients surgically treated at two referral centers.Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomasPhase II study of imatinib in advanced chordoma.Phase II study on lapatinib in advanced EGFR-positive chordoma.Development of transplantable human chordoma xenograft for preclinical assessment of novel therapeutic strategies.Imatinib in advanced chordoma: A retrospective case series analysis.Sacral Chordoma: Long-term Outcome of a Large Series of Patients Surgically Treated at Two Reference Centers.Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group.Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response.High-grade sarcomatous overgrowth in solitary fibrous tumors: a clinicopathologic study of 10 cases.Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapyHigh-dose continuous-infusion ifosfamide in advanced well-differentiated/dedifferentiated liposarcomaFeasibility of Preoperative Chemotherapy With or Without Radiation Therapy in Localized Soft Tissue Sarcomas of Limbs and Superficial Trunk in the Italian Sarcoma Group/Grupo Español de Investigación en Sarcomas Randomized Clinical Trial: Three VersResectable extra-pleural and extra-meningeal solitary fibrous tumours: A multi-centre prognostic study.Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.Prognostic relevance of ALT-associated markers in liposarcoma: a comparative analysis.Neoadjuvant chemotherapy in soft tissue sarcomas: latest evidence and clinical implications.Efficacy and economic value of adjuvant imatinib for gastrointestinal stromal tumorsProteomic detection of a large amount of SCGFα in the stroma of GISTs after imatinib therapy.Spontaneous regression of primary abdominal wall desmoid tumors: more common than previously thought.Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm--a position paper from the Italian and the French Sarcoma Group.Desmoid-type fibromatosis and pregnancy: a multi-institutional analysis of recurrence and obstetric risk.Sporadic extra abdominal wall desmoid-type fibromatosis: surgical resection can be safely limited to a minority of patients.Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.Identification of a gene expression driven progression pathway in myxoid liposarcoma.A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient.Epithelioid sarcoma in children and adolescents: a report from the Italian Soft Tissue Sarcoma Committee.Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis.Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution.Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution.Carney triad: case report and molecular analysis of gastric tumor.Myxoid/round cell and pleomorphic liposarcomas: prognostic factors and survival in a series of patients treated at a single institution.Cyclooxygenase-2 and platelet-derived growth factor receptors as potential targets in treating aggressive fibromatosis.
P50
Q28282621-1D4B3EE5-1A7A-4F67-981E-611150EE56F6Q30234500-6BF2064F-4477-4E39-82EA-92EE2DE65E1DQ30240235-05B24B49-4BD8-48AE-9CA8-9292E6B09683Q30607290-432FE6CD-E30B-4AA0-9812-A2DA520D1AA9Q33271347-F321F75C-8E1C-42B7-89FB-06343791B86BQ33272734-70A93B79-8E5F-48EB-8609-E12CD9A9EF97Q33273440-7ECA9F68-2019-436C-8B5E-964B1FCFCCA6Q33273555-1CCD4FAA-ECC4-4453-9A94-A77464DFE84BQ33273701-EE400073-12C1-4F17-8EE8-13E067D0F80EQ33274377-BFE36C29-13DB-4D61-95DD-9B0963BAFED2Q33274760-6604C842-63E8-4C91-8473-74D241F4A0D2Q33275064-DF4B63A0-9030-4711-A6E2-BB959D7991E7Q33275725-BBDFFE2B-E446-4709-A97F-EE2D66CDC2C8Q33275974-B499CCF2-6424-4F51-82D5-E2A7B06FB0EAQ33276384-FE3B7D37-4E35-40F9-A5B4-54D1C7AD65A0Q33389496-77DF98C8-656A-4C04-9DD1-A4906DFFF0ECQ33401339-64FF3AFD-EA12-49BC-A593-16DAFA1CAE91Q33416940-EADA00A8-7D76-4EB3-BBFA-C1DFA51DCFC2Q33420031-D77B90DB-29BA-482C-B3D3-D8453EC12229Q33425709-DAA23FB6-60D4-4AE9-8B0E-CAE7B1FD5F65Q33430341-11323C1B-FB8B-48C1-B965-3E36159E0DE8Q33441802-9DBFF333-A2F9-4DEA-8A5D-FC1A47C5F698Q33595051-0857ADD8-4CBB-494E-9F29-372515880C5AQ33757142-1F618843-065B-4F28-BA07-EA808E5B955EQ33777447-81D76690-F66C-4074-9E33-99E429BEEE5FQ34029127-FC620B95-3B73-4796-9D89-C8CFE95795F2Q34038265-0AF41A1B-36EE-4D53-A773-D9CE623412A9Q34039279-89F343A9-2D5E-43AF-98D6-F63EBDCE3B7CQ34039708-40E03DE7-E867-4D63-9AC6-7D36A2F78884Q34042707-1A003F43-E21A-4576-886F-1482E75A8C1AQ34102992-43DC76C4-C07F-4A11-AF2A-F4C6D46E0DF8Q34227540-3B9DE9C8-D09C-47ED-8A52-46F7EAC7023FQ34331384-03DA6AF1-3B63-42A1-84FD-EF4CE9826EC1Q34476210-2AF6B028-BB65-4F86-9E92-4108FAE86641Q34517908-E882E96D-9E57-4D49-883D-F24672687403Q34532365-C0AAD524-30E6-4093-A859-FB67BA722C2BQ34549587-64ED358B-55FA-4A57-99F8-1EA9D25EDC45Q34555107-B2ACCF31-64BC-490C-A66D-04390C912607Q34579626-D3544157-C6CC-4229-8075-5746FEC8895CQ34582442-3CA4A5F9-CDDA-43F8-B5FB-1A814BCB89E0
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Alessandro Gronchi
@ast
Alessandro Gronchi
@en
Alessandro Gronchi
@es
Alessandro Gronchi
@nl
Alessandro Gronchi
@sl
type
label
Alessandro Gronchi
@ast
Alessandro Gronchi
@en
Alessandro Gronchi
@es
Alessandro Gronchi
@nl
Alessandro Gronchi
@sl
prefLabel
Alessandro Gronchi
@ast
Alessandro Gronchi
@en
Alessandro Gronchi
@es
Alessandro Gronchi
@nl
Alessandro Gronchi
@sl
P1053
O-6589-2016
P106
P1153
6603959488
P21
P214
1633152821996201040000
P31
P3829
P496
0000-0002-4703-3534
P735
P7859
viaf-1633152821996201040000